Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends

Gad, Mohamed M.; Saad, Anas M.; Faisaluddin, Mohammed; Găman, Mihnea Alexandru; Ruhban, Inas A.; Jazieh, Khalid; Al‐Husseini, Muneer J.; Simons-Linares, C. Roberto; Sonbol, Mohamad Bassam; Estfan, Bassam

doi:10.1016/j.clinre.2020.03.024

Cited by 64 publications

(57 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 CCA is a relatively rare cancer with an incidence rate in the United States of 1.20 per 100 000 person-years from 2000 to 2015, based on data from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. 3 Estimated incidence rates in the United States for iCCA and eCCA during this period were 0.77 and 0.43 per 100 000 person-years, respectively. 3 Recent retrospective data analyses suggest that the incidence of CCA has increased in past decades in both the United States [3][4][5] and most European countries, 6 particularly that of iCCA.…”

Section: Introductionmentioning

confidence: 82%

“…3 Estimated incidence rates in the United States for iCCA and eCCA during this period were 0.77 and 0.43 per 100 000 person-years, respectively. 3 Recent retrospective data analyses suggest that the incidence of CCA has increased in past decades in both the United States [3][4][5] and most European countries, 6 particularly that of iCCA. In the United States, the annual percentage increases from 2003 to 2015 in iCCA and eCCA were 7.0 and 2.1, respectively.…”

Section: Introductionmentioning

confidence: 82%

See 1 more Smart Citation

Practical considerations in screening for genetic alterations in cholangiocarcinoma

2021

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit of standard chemotherapy for advanced disease. Comprehensive molecular profiling has revealed a diverse landscape of genomic alterations as oncogenic drivers in CCA. TP53 mutations, CDKN2A/B loss, and KRAS mutations are the most common genetic alterations in CCA. However, intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA) differ substantially in the frequency of many alterations. This includes actionable alterations, such as isocitrate dehydrogenase 1 (IDH1) mutations and a large variety of FGFR2 rearrangements, which are found in up to 29% and w10% of patients with iCCA, respectively, but are rare in eCCA. FGFR2 rearrangements are currently the only genetic alteration in CCA for which a targeted therapy, the fibroblast growth factor receptor 1-3 inhibitor pemigatinib, has been approved. However, favorable phase III results for IDH1-targeted therapy with ivosidenib in iCCA have been published, and numerous other alterations are actionable by targeted therapies approved in other indications. Recent advances in next-generation sequencing (NGS) have led to the development of assays that allow comprehensive genomic profiling of large gene panels within 2-3 weeks, including in vitro diagnostic tests approved in the United States. These assays vary regarding acceptable source material (tumor tissue or peripheral whole blood), genetic source for library construction (DNA or RNA), target selection technology, gene panel size, and type of detectable genomic alterations. While some large commercial laboratories offer rapid and comprehensive genomic profiling services based on proprietary assay platforms, clinical centers may use commercial genomic profiling kits designed for clinical research to develop their own customized laboratory-developed tests. Large-scale genomic profiling based on NGS allows for a detailed and precise molecular diagnosis of CCA and provides an important opportunity for improved targeted treatment plans tailored to the individual patient's genetic signature.

show abstract

Section: Introductionmentioning

confidence: 82%

Section: Introductionmentioning

confidence: 82%

Practical considerations in screening for genetic alterations in cholangiocarcinoma

2021

View full text Add to dashboard Cite

show abstract

“…Furthermore, the incidence and mortality rate of CCA increased between 2000–2015. [ 14 ] To date, however, ICCA and ECCA have rarely been compared because of difficulties in diagnosis and follow-up. [ 15 ] Concerning the CCA guidelines, an evaluation found that some current guidelines had poor applicability and lacked rigor in their development, although the proportion was small.…”

Section: Discussionmentioning

confidence: 99%

Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma

et al. 2021

View full text Add to dashboard Cite

To date, extrahepatic cholangiocarcinoma (ECCA) and intrahepatic cholangiocarcinoma (ICCA) have rarely been compared; therefore, we attempted to learn more about the rates of metastasis and survival in both ICCA and ECCA. Data of patients in the SEER database diagnosed with ICCA or ECCA were extracted to analyse the rate of metastasis and survival. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for metastasis. Propensity score matching (PSM) was used to compare survival rates between ECCA and ICCA. Data from a total of 15,751 patients diagnosed with ICCA or ECCA were extracted to analyse the rate of metastasis. Metastasis was more common in ECCA than ICCA (42.62% vs. 31.46%, P < .05), while ICCA in the T1 stage had a lower rate of metastasis (25.35% vs. 30.61%, P < .05). Age, pathology grade, tumour size, lymph node metastasis and T stage were independent risk factors for metastasis in both ECCA and ICCA. There was an inverse correlation between age and metastasis in both ICCA and ECCA. Moreover, PSM demonstrated that patients with ECCA had a better prognosis than patients with ICCA. Patients with ICCA in the T1 stage had better survival than those with ECCA in the T1 stage. Our study was the first to compare the rates of metastasis and survival between ECCA and ICCA. We observed an inverse association between age and metastasis, that patients with ECCA had a better prognosis than patients with ICCA, and that patients with ECCA in the T1 stage had worse survival than patients with ICCA in the T1 stage.

show abstract

“…Many studies have shown that race disparities commonly exist in incidence, progression, pathological classification, and prognosis of gastrointestinal tumors. [ 31 , 32 ] This phenomenon also occurs in gastric cancer and esophageal cancer. [ 33 – 36 ] Gu et al also found that gene expression levels in gastric cancer vary with race [ 37 ] in his studies.…”

Section: Discussionmentioning

confidence: 99%

Identification of biomarkers associated with diagnosis and prognosis of gastroesophageal junction adenocarcinoma–a study based on integrated bioinformatics analysis in GEO and TCGA database

Song

Jian-guo

et al. 2020

Medicine

View full text Add to dashboard Cite

Gastroesophageal junction adenocarcinoma (GEJAC) is a malignant tumor with high mortality. Its incidence has increased sharply all over the world in recent years. The study aims to search for potential biomarkers for the diagnosis and prognosis of GEJAC based on the Gene Expression Omnibus database (GEO) database and The Cancer Genome Atlas (TCGA) database. Microarray dataset (GSE96668 and GSE74553) of GEJAC was downloaded from the GEO. After screening overlapping differentially expressed genes (DEGs) by GEO2R and Wayne map, functional enrichment analysis of the DEGs was performed by the DAVID database. Then, a protein–protein interaction (PPI) network was constructed, and the hub gene was identified by using STRING and Cytoscape, as well as the diagnostic value of hub genes was evaluated by the receiver operating characteristic (ROC) curves. Finally, the gene transcriptome profiles of gastric cancer named TCGA-STAD were downloaded from TCGA database to screen the potential prognostic genes and construct the prognostic risk model using Cox proportional hazards regression. Meanwhile, the Kaplan–Meier curve and time-dependent ROC curve were adopted to test the prognostic value of the prognostic gene signature. In this study, we identified 10 hub genes that might have high diagnostic value for GEJAC, and inferred that they might be involved in the occurrence and development of GEJAC. Moreover, we conducted a survival prediction model consisting of 6 genes and proved that they have value to some extent in predicting prognosis for GEJAC patients.

show abstract

Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends

Cited by 64 publications

References 25 publications

Practical considerations in screening for genetic alterations in cholangiocarcinoma

Practical considerations in screening for genetic alterations in cholangiocarcinoma

Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma

Identification of biomarkers associated with diagnosis and prognosis of gastroesophageal junction adenocarcinoma–a study based on integrated bioinformatics analysis in GEO and TCGA database

Contact Info

Product

Resources

About